ROBERT COLEMAN

TitleProfessor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Coleman RL, Beck JT, Baranda JC, Jacobs I, Smoyer KE, Lee LJ, Askerova Z, McGinnis J, Ganti AK. The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials. Oncology. 2021 Apr 06; 1-10. PMID: 33823518.
      Citations:    
    2. Liou SH, Singh SK, Singer RH, Coleman RA, Liu WL. Structure of the p53/RNA polymerase II assembly. Commun Biol. 2021 Mar 25; 4(1):397. PMID: 33767390.
      Citations:    
    3. Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Ther. 2021 Mar 22. PMID: 33753870.
      Citations:    Fields:    
    4. Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecol Oncol. 2021 Mar 19. PMID: 33752918.
      Citations:    Fields:    
    5. Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer. 2021 Mar 19. PMID: 33740262.
      Citations:    Fields:    
    6. Alholm Z, Monk BJ, Ting J, Pulgar S, Boyd M, Sudharshan L, Bains S, Nicacio L, Coleman RL. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecol Oncol. 2021 Mar 17. PMID: 33741208.
      Citations:    Fields:    
    7. Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 Mar 15. PMID: 33736856.
      Citations:    Fields:    
    8. Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 Mar 12. PMID: 33722417.
      Citations:    Fields:    
    9. Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol. 2021 Mar 11. PMID: 33715892.
      Citations:    Fields:    
    10. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4). PMID: 33572451.
      Citations:    
    11. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 Mar; 160(3):777-785. PMID: 33563487.
      Citations: 1     Fields:    
    12. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 Apr; 161(1):104-112. PMID: 33551196.
      Citations:    Fields:    
    13. Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE, Greenfield DM. Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2021 Feb; 29(2):1145. PMID: 33216165.
      Citations:    Fields:    
    14. Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, Eastell R. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. Br J Cancer. 2021 Jan 22. PMID: 33495601.
      Citations:    Fields:    
    15. Eskander RN, Pothuri B, Randall L, O'Malley D, Slomovitz B, Moore K, Coleman R, Herzog T, Monk BJ, Copeland L. Clinical trials, adaptability and the COVID-19 pandemic. Gynecol Oncol Rep. 2021 Feb; 35:100680. PMID: 33319009.
      Citations:    
    16. Singh K, Gillett S, Ireson J, Hills A, Tidy JA, Coleman RE, Hancock BW, Winter MC. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia. Int J Cancer. 2021 May 01; 148(9):2335-2344. PMID: 33210289.
      Citations:    Fields:    
    17. Coleman RL. The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us? J Gynecol Oncol. 2021 Jan; 32(1):e20. PMID: 33300315.
      Citations:    Fields:    
    18. Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020 12; 21(12):1661-1672. PMID: 33271095.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    19. Chelariu-Raicu A, Nick A, Urban R, Gordinier M, Leuschner C, Bavisotto L, Molin GZD, Whisnant JK, Coleman RL. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Gynecol Oncol. 2021 Feb; 160(2):418-426. PMID: 33243443.
      Citations: 1     Fields:    
    20. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 Jan; 31(1):92-97. PMID: 33154095.
      Citations:    Fields:    
    21. Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L. Bone metastases. Nat Rev Dis Primers. 2020 10 15; 6(1):83. PMID: 33060614.
      Citations: 3     Fields:    
    22. Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774. PMID: 33037105.
      Citations:    Fields:    
    23. Slomovitz B, de Haydu C, Taub M, Coleman RL, Monk BJ. Asbestos and ovarian cancer: examining the historical evidence. Int J Gynecol Cancer. 2021 Jan; 31(1):122-128. PMID: 33037108.
      Citations:    Fields:    
    24. Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1733-1737. PMID: 33020204.
      Citations:    Fields:    
    25. Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition in recurrent ovarian cancer. Clin Adv Hematol Oncol. 2020 Oct; 18(10):647-655. PMID: 33201871.
      Citations:    Fields:    Translation:Humans
    26. Onstad M, Coleman RL, Westin SN. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs. 2020 Oct; 80(15):1525-1535. PMID: 32852746.
      Citations: 1     Fields:    
    27. Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. Gynecol Oncol. 2020 12; 159(3):604-606. PMID: 32994055.
      Citations:    Fields:    
    28. Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Mol Cancer Ther. 2020 Sep 17. PMID: 32943548.
      Citations:    
    29. Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. Int J Gynecol Cancer. 2020 10; 30(10):1608-1618. PMID: 32928926.
      Citations:    Fields:    
    30. Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition as frontline therapy in ovarian cancer. Clin Adv Hematol Oncol. 2020 Sep; 18(9):550-556. PMID: 33006584.
      Citations:    Fields:    Translation:Humans
    31. Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2020 10; 159(1):101-111. PMID: 32861537.
      Citations: 2     Fields:    
    32. Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol. 2020 10 20; 38(30):3494-3505. PMID: 32840418.
      Citations: 1     Fields:    Translation:Humans
    33. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 11 10; 38(32):3753-3762. PMID: 32822286.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    34. Chelariu-Raicu A, Coleman RL. Breast cancer (BRCA) gene testing in ovarian cancer. Chin Clin Oncol. 2020 Oct; 9(5):63. PMID: 32819112.
      Citations: 1     Fields:    
    35. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15. PMID: 32805208.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    36. Park SR, Hauver J, Zhang Y, Revyakin A, Coleman RA, Tjian R, Chu S, Pertsinidis A. A Single-Molecule Surface-Based Platform to Detect the Assembly and Function of the Human RNA Polymerase II Transcription Machinery. Structure. 2020 12 01; 28(12):1337-1343.e4. PMID: 32763141.
      Citations:    Fields:    
    37. Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C, Collinson FJ, Coleman RE, James N, Francis R, Reid DM, McCloskey E. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol. 2020 Dec; 25:100311. PMID: 32995252.
      Citations:    
    38. Coleman R. Bisphosphonates and breast cancer - From cautious palliation to saving lives. Bone. 2020 11; 140:115570. PMID: 32745688.
      Citations: 1     Fields:    
    39. Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87. PMID: 32723679.
      Citations:    Fields:    
    40. Nitecki R, Rauh-Hain JA, Melamed A, Scambia G, Pareja R, Coleman RL, Ramirez PT, Fagotti A. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). Int J Gynecol Cancer. 2020 09; 30(9):1450-1454. PMID: 32690591.
      Citations:    Fields:    
    41. Fujiwara K, Quinn MA, Coleman RL, Angioli R. Two viral infections in Japan. Int J Gynecol Cancer. 2020 08; 30(8):1258-1259. PMID: 32675255.
      Citations: 1     Fields:    
    42. Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul; 63(4):417-431. PMID: 32689770.
      Citations: 1     
    43. Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735. PMID: 32499298.
      Citations: 1     Fields:    
    44. Frumovitz M, Obermair A, Coleman RL, Pareja R, Lopez A, Ribero R, Isla D, Rendon G, Bernardini MQ, Buda A, Moretti-Marquez R, Zevallos A, Vieira MA, Zhu T, Land RP, Nicklin J, Asher R, Robledo KP, Gebski V, Ramirez PT. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020 06; 21(6):851-860. PMID: 32502445.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    45. Margul D, Coleman RL, Herzog TJ. The current status of secondary cytoreduction in ovarian cancer: a systematic review. Clin Adv Hematol Oncol. 2020 Jun; 18(6):332-343. PMID: 32649655.
      Citations:    Fields:    Translation:Humans
    46. Elshaikh MA, Modh A, Jhingran A, Biagioli MC, Coleman RL, Gaffney DK, Harkenrider MM, Heskett K, Jolly S, Kidd E, Lee LJ, Li L, Portelance L, Sherertz T, Venkatessan AM, Wahl AO, Yashar CM, Small W. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma. Gynecol Oncol. 2020 08; 158(2):460-466. PMID: 32475772.
      Citations:    Fields:    
    47. Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588. PMID: 32450190.
      Citations: 1     Fields:    
    48. Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, Amant F, van Gent MDJM, Huntsman DG, Coleman RL, Westin SN, Yates MS, Krakstad C, Quinn MA, Janda M, Obermair A. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1811-1823. PMID: 32381512.
      Citations: 2     Fields:    
    49. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 05; 21(5):710-722. PMID: 32359490.
      Citations: 2     Fields:    Translation:Humans
    50. Monk BJ, Coleman RL, Moore KN, Herzog TJ, Secord AA, Matulonis UA, Slomovitz BM, Guntupalli SR, O'Malley DM. COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020 07; 158(1):34-36. PMID: 32370991.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    51. Armbruster SD, Fellman BM, Jhingran A, Eifel PJ, Klopp AH, Coleman RL, Ramondetta LM, Frumovitz M. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222. PMID: 32338316.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    52. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438.
      Citations: 6     Fields:    
    53. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun; 86:102017. PMID: 32335505.
      Citations: 27     Fields:    Translation:Humans
    54. Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer. Data Brief. 2020 Jun; 30:105465. PMID: 32346557.
      Citations:    
    55. Coleman RL. Innovation abounds in cancer therapy. Int J Gynecol Cancer. 2020 04; 30(4):424-425. PMID: 32193218.
      Citations:    Fields:    Translation:Humans
    56. Coleman R, Zhou Y, Chan A. Adjuvant denosumab in early breast cancer - Authors' reply. Lancet Oncol. 2020 03; 21(3):e125. PMID: 32135109.
      Citations: 1     Fields:    
    57. Arend R, Westin SN, Coleman RL. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer. 2020 05; 30(5):684-694. PMID: 32079709.
      Citations:    Fields:    Translation:HumansCells
    58. Coleman RL. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply. N Engl J Med. 2020 02 13; 382(7):686. PMID: 32053314.
      Citations:    Fields:    Translation:Humans
    59. Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, Terranova C. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020 Apr; 134:56-61. PMID: 32059825.
      Citations: 1     Fields:    Translation:Humans
    60. Rees M, Angioli R, Coleman RL, Glasspool RM, Plotti F, Simoncini T, Terranova C. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Int J Gynecol Cancer. 2020 04; 30(4):428-433. PMID: 32046979.
      Citations:    Fields:    Translation:Humans
    61. Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol. 2020 05; 157(2):386-391. PMID: 32037195.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    62. Drosopoulos WC, Vierra DA, Kenworthy CA, Coleman RA, Schildkraut CL. Dynamic Assembly and Disassembly of the Human DNA Polymerase d Holoenzyme on the Genome In Vivo. Cell Rep. 2020 02 04; 30(5):1329-1341.e5. PMID: 32023453.
      Citations: 2     Fields:    Translation:HumansCells
    63. Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546. PMID: 32083163.
      Citations:    
    64. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725. PMID: 31969252.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    65. Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193. PMID: 32014370.
      Citations: 3     Fields:    
    66. Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020 03; 156(3):535-544. PMID: 31924332.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    67. Herzog TJ, Secord AA, Coleman RL, Naumann RW. European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies. Gynecol Oncol. 2020 02; 156(2):265-270. PMID: 31911006.
      Citations:    Fields:    Translation:Humans
    68. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. 2020 01 01; 112(1):38-45. PMID: 30924863.
      Citations: 1     Fields:    Translation:Humans
    69. Naumann RW, Coleman RL, Brown J, Moore KN. Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444]. Gynecol Oncol. 2020 Feb; 156(2):512-513. PMID: 31859001.
      Citations:    Fields:    
    70. Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). Clin Cancer Res. 2020 04 01; 26(7):1574-1585. PMID: 31836609.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    71. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422. PMID: 31714586.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    72. Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 03 15; 26(6):1220-1228. PMID: 31796521.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    73. Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):60-72. PMID: 31806543.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    74. Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K. Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opin Emerg Drugs. 2019 12; 24(4):239-253. PMID: 31755325.
      Citations: 1     Fields:    Translation:Humans
    75. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 01; 30(1):89-93. PMID: 31792084.
      Citations: 5     Fields:    Translation:Humans
    76. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589. PMID: 31772388.
      Citations: 1     Fields:    Translation:HumansCells
    77. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939. PMID: 31722153.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    78. Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE, Snowden JA, Ross RJ. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019 11; 16(11):e1002960. PMID: 31714912.
      Citations: 2     Fields:    Translation:Humans
    79. Coleman R. Clinical benefits of bone targeted agents in early breast cancer. Breast. 2019 Nov; 48 Suppl 1:S92-S96. PMID: 31839171.
      Citations: 2     Fields:    Translation:Humans
    80. Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2020; 21(2):147-156. PMID: 31640461.
      Citations: 2     Fields:    
    81. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587. PMID: 31628143.
      Citations: 1     Fields:    Translation:Humans
    82. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428. PMID: 31623857.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    83. Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2019 Dec; 2(4):505-515. PMID: 32025647.
      Citations: 8     
    84. Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. Am J Obstet Gynecol. 2020 03; 222(3):249.e1-249.e10. PMID: 31586602.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    85. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415. PMID: 31562800.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    86. Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D. An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol. 2019 Dec; 19:100261. PMID: 31667062.
      Citations: 1     
    87. Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260. PMID: 32139271.
      Citations: 2     Fields:    
    88. Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecol Oncol. 2019 10; 155(1):126-134. PMID: 31416612.
      Citations: 2     Fields:    Translation:Humans
    89. Lheureux S, Mirza M, Coleman R. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. J Clin Oncol. 2019 09 20; 37(27):2449-2459. PMID: 31403862.
      Citations: 1     Fields:    Translation:HumansCells
    90. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol. 2019 08; 154(2):255-258. PMID: 31331494.
      Citations:    Fields:    Translation:Humans
    91. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530. PMID: 31353053.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    92. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Int J Gynecol Cancer. 2019 09; 29(7):1094-1097. PMID: 31320391.
      Citations:    Fields:    Translation:Humans
    93. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019 07 16; 33(7). PMID: 31365748.
      Citations: 3     Fields:    Translation:Humans
    94. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. PMID: 31216226.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    95. Falchook G, Coleman RL, Schilder RJ. Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):910-911. PMID: 31021370.
      Citations:    Fields:    Translation:Humans
    96. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546. PMID: 31191824.
      Citations: 5     Fields:    
    97. Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clin Cancer Res. 2019 08 15; 25(16):4874-4880. PMID: 31126961.
      Citations: 3     Fields:    Translation:Humans
    98. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer. 2019 May 22. PMID: 31118216.
      Citations: 1     Fields:    
    99. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res. 2019 May 15; 25(10):3194. PMID: 31092618.
      Citations:    Fields:    
    100. Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone. 2019 07; 124:83-88. PMID: 31028957.
      Citations:    Fields:    Translation:Humans
    101. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979. PMID: 30926640.
      Citations: 1     Translation:HumansAnimals
    102. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019 07 01; 125(13):2154-2163. PMID: 30913308.
      Citations: 1     Fields:    Translation:Humans
    103. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580. PMID: 30880072.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    104. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972. PMID: 30835824.
      Citations: 6     Fields:    Translation:Humans
    105. Naumann RW, Coleman RL, Brown J, Moore KN. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019 05; 153(2):436-444. PMID: 30765149.
      Citations: 4     Fields:    Translation:Humans
    106. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019 03 04; 216(3):688-703. PMID: 30710055.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    107. Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J Pathol. 2019 03; 247(3):381-391. PMID: 30426503.
      Citations: 13     Fields:    Translation:HumansCells
    108. Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clin Cancer Res. 2019 05 01; 25(9):2769-2782. PMID: 30670488.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    109. Uccella S, Fagotti A, Zannoni GF, Coleman RL. Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. Int J Gynecol Cancer. 2019 01; 29(1):216-220. PMID: 30640707.
      Citations: 1     Fields:    Translation:Humans
    110. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. PMID: 30347019.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    111. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 01; 20(1):e15-e28. PMID: 30614472.
      Citations: 29     Fields:    Translation:Humans
    112. Armbruster S, Coleman RL, Rauh-Hain JA. Management and Treatment of Recurrent Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):965-982. PMID: 30390768.
      Citations: 8     Fields:    Translation:Humans
    113. Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep. 2019 Feb; 27:1-4. PMID: 30519622.
      Citations: 2     
    114. Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 11 15; 19(12):1. PMID: 30535808.
      Citations: 12     Fields:    Translation:Humans
    115. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2019 02; 9(2):210-219. PMID: 30425037.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    116. D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol. 2019 Apr; 15:004-4. PMID: 30937279.
      Citations: 26     
    117. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526. PMID: 29860375.
      Citations: 7     Fields:    Translation:Humans
    118. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018 Nov 15; 379(20):1895-1904. PMID: 30380365.
      Citations: 140     Fields:    Translation:HumansCTClinical Trials
    119. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647.
      Citations: 1     Fields:    Translation:Humans
    120. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226.
      Citations:    Fields:    Translation:Humans
    121. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435.
      Citations:    Fields:    Translation:Humans
    122. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554. PMID: 30095787.
      Citations: 7     Fields:    Translation:Humans
    123. Richardson DL, Coleman RL, Sill MW. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299. PMID: 29978183.
      Citations: 2     Fields:    Translation:Humans
    124. Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE, Greenfield DM. Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2019 May; 27(5):1755-1763. PMID: 30143894.
      Citations: 1     Fields:    Translation:Humans
    125. Zibetti Dal Molin G, Abrahão CM, Coleman RL, Maluf FC. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. Gynecol Oncol Res Pract. 2018; 5:6. PMID: 30147940.
      Citations: 2     
    126. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330. PMID: 30190789.
      Citations: 2     Fields:    
    127. Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018 Dec; 14(30):3101-3110. PMID: 30105925.
      Citations: 1     Fields:    Translation:Humans
    128. Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018 09 15; 78(18):5300-5314. PMID: 30065048.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    129. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483. PMID: 29977351.
      Citations: 5     
    130. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis. 2018 08; 35(5-6):521-533. PMID: 29931499.
      Citations: 5     Fields:    Translation:Humans
    131. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. PMID: 29863451.
      Citations: 54     Fields:    Translation:Humans
    132. Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug; 171(1):11-20. PMID: 29725889.
      Citations: 10     Fields:    Translation:HumansAnimals
    133. Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM. Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecol Oncol. 2018 06; 149(3):605-611. PMID: 29699802.
      Citations: 2     Fields:    Translation:Humans
    134. Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 04 11; 10(436). PMID: 29643228.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    135. Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018 11; 6(11):901-910. PMID: 29572126.
      Citations: 10     Fields:    Translation:Humans
    136. Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326. PMID: 29560266.
      Citations: 10     Fields:    
    137. Holmes AM, Emmans CJ, Coleman R, Smith TE, Hosie CA. Effects of transportation, transport medium and re-housing on Xenopus laevis (Daudin). Gen Comp Endocrinol. 2018 09 15; 266:21-28. PMID: 29545087.
      Citations: 2     Fields:    Translation:Animals
    138. Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018 03; 37(1):189-196. PMID: 29380085.
      Citations: 17     Fields:    Translation:HumansAnimals
    139. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202. PMID: 29242937.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    140. Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018 02; 102(2):251-264. PMID: 29353450.
      Citations: 7     Fields:    Translation:Humans
    141. Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7. PMID: 29352368.
      Citations:    Fields:    Translation:Humans
    142. Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R, Wyld L. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 01; 36(1):29-38. PMID: 28770452.
      Citations: 2     Fields:    Translation:Humans
    143. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473. PMID: 29237804.
      Citations: 1     Translation:HumansAnimalsCells
    144. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    145. Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA. A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. Gynecol Oncol Res Pract. 2017; 4:16. PMID: 29158911.
      Citations: 2     
    146. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57. PMID: 29122619.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    147. Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017 11; 18(11):1543-1552. PMID: 29037984.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    148. Liu WL, Coleman RA, Singh SK. A new era of studying p53-mediated transcription activation. Transcription. 2018; 9(2):102-107. PMID: 28795863.
      Citations: 1     Fields:    Translation:HumansCells
    149. Baselga J, Coleman RE, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2017 Nov; 119:113-122. PMID: 29042085.
      Citations: 11     Fields:    Translation:Humans
    150. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28; 390(10106):1949-1961. PMID: 28916367.
      Citations: 219     Fields:    Translation:HumansCTClinical Trials
    151. D'Oronzo S, Brown J, Coleman R. The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol. 2017 Nov; 9:1-9. PMID: 28948139.
      Citations: 19     
    152. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 11; 147(2):267-275. PMID: 28882436.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    153. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046. PMID: 28855350.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    154. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505. PMID: 29228548.
      Citations: 16     Fields:    
    155. Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 10; 147(1):3-10. PMID: 28844539.
      Citations: 5     Fields:    Translation:Humans
    156. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    157. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar; 73(3):427-435. PMID: 28705540.
      Citations: 18     Fields:    
    158. D'Oronzo S, Brown J, Coleman R. The value of biomarkers in bone metastasis. Eur J Cancer Care (Engl). 2017 Nov; 26(6). PMID: 28653449.
      Citations: 14     Fields:    Translation:HumansCells
    159. Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017 08; 146(2):217-224. PMID: 28596016.
      Citations: 17     Fields:    Translation:Humans
    160. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 07; 18(7):929-945. PMID: 28600210.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    161. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2017 09; 7(9):984-998. PMID: 28588062.
      Citations: 64     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    162. Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):755-769. PMID: 28479233.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    163. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol. 2017 Aug 01; 35(22):2507-2514. PMID: 28467729.
      Citations: 3     Fields:    Translation:Humans
    164. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791. PMID: 28438473.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    165. Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017 Jun; 7:1-12. PMID: 28413771.
      Citations: 34     
    166. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123. PMID: 28265009.
      Citations: 17     Translation:HumansAnimals
    167. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111. PMID: 28221866.
      Citations: 21     Fields:    Translation:Humans
    168. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017 Apr; 145(1):27-31. PMID: 28209497.
      Citations: 16     Fields:    Translation:Humans
    169. Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691. PMID: 28174234.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    170. Westin SN, Coleman RL. Individualized Medicine in Ovarian Cancer: Are We There Yet? Gynecol Oncol. 2017 02; 144(2):229-231. PMID: 28089051.
      Citations:    Fields:    Translation:Humans
    171. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Corrigendum to 'Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363]. Gynecol Oncol. 2017 02; 144(2):448. PMID: 28089052.
      Citations:    Fields:    
    172. Coleman RA, Liang C, Patel R, Ali S, Mukherjee J. Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18F-FDG PET Imaging. Mol Imaging. 2017 01 01; 16:1536012117704557. PMID: 28654383.
      Citations: 5     Fields:    Translation:Animals
    173. Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017 01; 71:1-6. PMID: 27930924.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    174. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 01; 18(1):75-87. PMID: 27908594.
      Citations: 244     Fields:    Translation:HumansCTClinical Trials
    175. Singh SK, Qiao Z, Song L, Jani V, Rice W, Eng E, Coleman RA, Liu WL. Structural visualization of the p53/RNA polymerase II assembly. Genes Dev. 2016 11 15; 30(22):2527-2537. PMID: 27920087.
      Citations: 7     Fields:    Translation:HumansCells
    176. Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016 Nov 15; 7(46):75571-75584. PMID: 27765923.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    177. Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D, Coleman RE. Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study. J Bone Oncol. 2017 Nov; 9:48-54. PMID: 29234591.
      Citations: 1     
    178. Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 12 20; 34(36):4345-4353. PMID: 27998236.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    179. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct; 143(1):27-34. PMID: 27546885.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    180. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 10 01; 34(28):3460-73. PMID: 27502591.
      Citations: 61     Fields:    Translation:Humans
    181. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer. 2017 02; 15(1):42-52.e8. PMID: 27613490.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    182. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 10; 143(1):3-15. PMID: 27650684.
      Citations: 35     Fields:    Translation:Humans
    183. Coleman RE. Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer. Oncology (Williston Park). 2016 08; 30(8):695-702. PMID: 27528238.
      Citations: 7     Fields:    Translation:Humans
    184. Macdonald MC, Hancock BW, Winter MC, Coleman RE, Tidy JA. Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006. J Reprod Med. 2016 Aug; 61(7-8):341-346. PMID: 30408379.
      Citations:    Fields:    Translation:Humans
    185. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591]. Gynecol Oncol. 2016 10; 143(1):224. PMID: 27477189.
      Citations:    Fields:    
    186. Coleman RL, Monk BJ. Saving the best treatment for last? Ann Oncol. 2016 09; 27(9):1656-8. PMID: 27456298.
      Citations:    Fields:    
    187. Chuang LT, Randall TC, Denny L, Johnston CM, Schmeler KM, Covens AL, Cibula D, Bookman MA, Rawal S, DePetrillo D, Nam JH, Goodman A, Naik R, Manchanda R, Gaffney DK, Small W, Creutzberg C, Rattray C, Kesic V, Paraja R, Eiken M, Belleson K, Coleman RL, Barakat RR, Trimble EL, Quinn M. Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. Int J Gynecol Cancer. 2016 07; 26(6):1186-8. PMID: 27327155.
      Citations: 4     Fields:    Translation:Humans
    188. Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. Eur Urol. 2016 11; 70(5):875-883. PMID: 27344296.
      Citations: 9     Fields:    Translation:Humans
    189. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      Citations: 5     Fields:    Translation:Humans
    190. Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016 06; 157(2):401. PMID: 27165143.
      Citations:    Fields:    
    191. Coleman RL. Foreword. Gynecol Oncol. 2016 06; 141 Suppl 1:1. PMID: 27267443.
      Citations:    Fields:    Translation:Humans
    192. Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238. PMID: 30906877.
      Citations: 4     
    193. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86. PMID: 27217446.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    194. Takekuma M, Wong KK, Coleman RL. A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 2016; 3:5. PMID: 27231576.
      Citations: 8     
    195. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6. PMID: 26937753.
      Citations:    Fields:    Translation:Humans
    196. Coleman R. Bone targeted treatments in cancer - The story so far. J Bone Oncol. 2016 Sep; 5(3):90-92. PMID: 27761363.
      Citations: 3     
    197. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56. PMID: 27087632.
      Citations: 19     Fields:    Translation:Humans
    198. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol. 2016 06; 141(3):588-591. PMID: 27079212.
      Citations: 10     Fields:    Translation:Humans
    199. Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 06; 141(3):405-409. PMID: 27049967.
      Citations: 6     Fields:    Translation:Humans
    200. Wilson C, Coleman R. Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncol. 2016 Apr; 2(4):423-4. PMID: 26794938.
      Citations: 2     Fields:    Translation:Humans
    201. Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1. PMID: 27016221.
      Citations: 1     Fields:    Translation:Humans
    202. Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 07; 76(10):905-16. PMID: 27004570.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    203. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52. PMID: 27009216.
      Citations: 13     Translation:HumansAnimalsCells
    204. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263. PMID: 26968641.
      Citations: 17     Fields:    Translation:Humans
    205. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016 Jul; 215(1):82.e1-82.e11. PMID: 26970494.
      Citations: 21     Fields:    Translation:Humans
    206. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. Gynecol Oncol. 2016 05; 141(2):357-363. PMID: 26946092.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    207. Coleman R. Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Semin Nucl Med. 2016 Mar; 46(2):99-104. PMID: 26897713.
      Citations: 15     Fields:    Translation:HumansAnimals
    208. Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJ, Thomas G, Coleman RE. Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. J Bone Oncol. 2016 Mar; 5(1):43-9. PMID: 26998426.
      Citations: 1     
    209. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 03; 17:63. PMID: 26841937.
      Citations:    Fields:    
    210. Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143. PMID: 26849037.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    211. Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA. Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Res Treat. 2016 Jan; 155(2):303-11. PMID: 26783036.
      Citations:    Fields:    Translation:Humans
    212. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jan 13; (1):CD008891. PMID: 26760424.
      Citations: 6     Fields:    Translation:Humans
    213. Coleman RA, Liu Z, Darzacq X, Tjian R, Singer RH, Lionnet T. Imaging Transcription: Past, Present, and Future. Cold Spring Harb Symp Quant Biol. 2015; 80:1-8. PMID: 26763984.
      Citations: 17     Fields:    Translation:AnimalsCells
    214. Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst. 2016 Apr; 108(4). PMID: 26757732.
      Citations: 25     Fields:    Translation:HumansCells
    215. Coleman RL. Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol. 2016 Feb; 13(2):71-2. PMID: 26718108.
      Citations: 5     Fields:    Translation:Humans
    216. Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016 01; 155(1):151-7. PMID: 26687384.
      Citations: 9     Fields:    Translation:Humans
    217. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015 Dec 16; 16:575. PMID: 26673577.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    218. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27; 387(10021):866-73. PMID: 26686313.
      Citations: 30     Fields:    Translation:Humans
    219. Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol. 2016 Feb; 140(2):193-8. PMID: 26631607.
      Citations: 13     Fields:    Translation:Humans
    220. Archibald K, Drake T, Coleman R. Barriers to the Uptake of Human-based Test Methods, and How to Overcome Them. Altern Lab Anim. 2015 Nov; 43(5):301-8. PMID: 26551287.
      Citations: 2     Fields:    Translation:HumansAnimals
    221. Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86. PMID: 26516159.
      Citations: 5     Translation:HumansAnimalsCells
    222. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622. PMID: 26481148.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    223. Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst. 2015 Dec; 107(12):djv256. PMID: 26376684.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    224. Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM, Han TS. Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clin Endocrinol (Oxf). 2016 Feb; 84(2):296-304. PMID: 26248973.
      Citations: 2     Fields:    
    225. Castro MP, Whitcomb BP, Zajchowski DA, Coleman RL. Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. Gynecol Oncol Res Pract. 2015; 2:4. PMID: 27231564.
      Citations: 3     
    226. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51. PMID: 26301456.
      Citations: 63     Fields:    Translation:Humans
    227. Slomovitz BM, Coleman RL. Reply to G. Bogani et al. J Clin Oncol. 2015 Oct 20; 33(30):3516. PMID: 26240222.
      Citations:    Fields:    Translation:Humans
    228. Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. J Oncol Pharm Pract. 2016 Aug; 22(4):599-604. PMID: 26183293.
      Citations: 3     Fields:    Translation:Humans
    229. Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6. PMID: 26166806.
      Citations: 12     Fields:    Translation:Humans
    230. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
      Citations: 16     Fields:    Translation:Humans
    231. Bonneterre J, Hutt E, Bosq J, Graham JD, Powell MA, Leblanc E, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Gynecol Oncol. 2015 Sep; 138(3):663-7. PMID: 26142884.
      Citations: 2     Fields:    Translation:Humans
    232. Coleman R, Hadji P. Denosumab and fracture risk in women with breast cancer. Lancet. 2015 Aug 01; 386(9992):409-10. PMID: 26040500.
      Citations: 1     Fields:    Translation:Humans
    233. Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug; 138(2):267-71. PMID: 26037898.
      Citations: 5     Fields:    Translation:Humans
    234. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015 Aug; 138(2):472-7. PMID: 26022527.
      Citations: 9     Fields:    Translation:Humans
    235. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703. PMID: 26045339.
      Citations: 13     Fields:    Translation:HumansCells
    236. Coleman R, King T, Nicoara CD, Bader M, McCarthy L, Chandran H, Parashar K. Combined creatinine velocity and nadir creatinine: A reliable predictor of renal outcome in neonatally diagnosed posterior urethral valves. J Pediatr Urol. 2015 Aug; 11(4):214.e1-3. PMID: 26062970.
      Citations: 2     Fields:    Translation:Humans
    237. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97. PMID: 25878333.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    238. Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5. PMID: 25887099.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    239. Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475. PMID: 25833835.
      Citations: 6     Translation:HumansAnimalsCells
    240. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8. PMID: 25827290.
      Citations: 18     Fields:    Translation:Humans
    241. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun; 137(3):386-91. PMID: 25818403.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    242. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10; 33(14):1574-83. PMID: 25779558.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    243. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. Nat Rev Clin Oncol. 2015 Jun; 12(6):358-70. PMID: 25754949.
      Citations: 16     Fields:    Translation:Humans
    244. Herzog TJ, Coleman RL, Monk BJ, Armstrong DK, Alvarez RD. In assessing surrogate clinical trial end points: drug safety is a requisite. J Clin Oncol. 2015 May 01; 33(13):1511-2. PMID: 25732164.
      Citations:    Fields:    Translation:Humans
    245. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015 Mar; 34(1):41-52. PMID: 25564455.
      Citations: 35     Fields:    Translation:Humans
    246. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40. PMID: 25544368.
      Citations: 32     Fields:    Translation:HumansCells
    247. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45. PMID: 25707631.
      Citations: 61     Fields:    Translation:Humans
    248. Wilson C, Ottewell P, Coleman RE, Holen I. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer. 2015 Feb 14; 15:55. PMID: 25884855.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    249. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19. PMID: 25666164.
      Citations: 97     Fields:    Translation:HumansAnimals
    250. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65. PMID: 25502429.
      Citations: 5     Fields:    Translation:Humans
    251. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, Goossen H, Gounder V, Crosbie G, Hancock S, Diaz-Guilas S, Mainwaring P, Swindle P, Hart DN. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother. 2015 Feb-Mar; 38(2):71-6. PMID: 25658616.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    252. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6. PMID: 25624430.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    253. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. PMID: 25495490.
      Citations: 152     Fields:    Translation:HumansCTClinical Trials
    254. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    255. Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2015 Jan; 136(1):94-8. PMID: 25462203.
      Citations: 4     Fields:    Translation:Humans
    256. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59. PMID: 25416196.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    257. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61. PMID: 25388163.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    258. Coleman RL, Herzog TJ, Monk BJ, Dooner P. Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. Gynecol Oncol Res Pract. 2014; 1:1. PMID: 27231554.
      Citations: 1     
    259. Goyal A, Dodwell D, Reed MW, Coleman RE. Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice. J Clin Oncol. 2014 Dec 01; 32(34):3902. PMID: 25245444.
      Citations: 5     Fields:    Translation:Humans
    260. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol. 2014 Oct; 135(1):3-7. PMID: 25124162.
      Citations: 2     Fields:    Translation:Humans
    261. Kaur J, Khararjian A, Coleman RA, Constantinescu CC, Pan ML, Mukherjee J. Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using (18)F/(11)C-fallypride. Nucl Med Biol. 2014 Nov-Dec; 41(10):841-7. PMID: 25199843.
      Citations: 2     Fields:    Translation:Animals
    262. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014 Aug; 15(9):997-1006. PMID: 25035292.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    263. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91. PMID: 25026212.
      Citations: 110     Fields:    Translation:HumansAnimalsCells
    264. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer. 2014 Aug 26; 111(5):843-50. PMID: 25003664.
      Citations: 10     Fields:    Translation:Humans
    265. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9. PMID: 24952408.
      Citations: 4     Fields:    Translation:Humans
    266. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8):799-808. PMID: 24950985.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    267. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun; 15(7):738-46. PMID: 24836273.
      Citations: 118     Fields:    Translation:HumansCTClinical Trials
    268. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7. PMID: 24651628.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    269. Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J, Hancock BW. Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience. J Reprod Med. 2014 May-Jun; 59(5-6):195-8. PMID: 24937956.
      Citations: 1     Fields:    Translation:Humans
    270. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29. PMID: 24755674.
      Citations: 12     Translation:HumansAnimalsCells
    271. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8. PMID: 24756370.
      Citations: 25     Fields:    Translation:Humans
    272. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    273. Saxton JM, Scott EJ, Daley AJ, Woodroofe M, Mutrie N, Crank H, Powers HJ, Coleman RE. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Res. 2014 Apr 14; 16(2):R39. PMID: 24731917.
      Citations: 22     Fields:    Translation:Humans
    274. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat. 2014 Jun; 145(2):411-8. PMID: 24728613.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    275. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48. PMID: 24709487.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    276. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838.
      Citations: 20     Fields:    Translation:HumansCells
    277. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50. PMID: 24634380.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    278. Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer. 2014 Apr; 21(2):327-41. PMID: 24413608.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    279. George SC, Smith TE, Mac Cana PS, Coleman R, Montgomery WI. Physiological stress in the Eurasian badger (Meles meles): effects of host, disease and environment. Gen Comp Endocrinol. 2014 May 01; 200:54-60. PMID: 24607571.
      Citations: 4     Fields:    Translation:AnimalsCells
    280. Graybill WS, Coleman RL. Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol. 2014 Mar; 10(4):541-8. PMID: 24754586.
      Citations: 5     Fields:    Translation:HumansAnimals
    281. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol. 2014 Apr; 133(1):100-4. PMID: 24534359.
      Citations: 5     Fields:    Translation:Humans
    282. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55. PMID: 24486585.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    283. Pandey S, Venugopal A, Kant R, Coleman R, Mukherjee J. ¹²4I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors. Nucl Med Biol. 2014 May-Jun; 41(5):426-31. PMID: 24602412.
      Citations: 4     Fields:    Translation:Animals
    284. Hofbauer LC, Rachner TD, Coleman RE, Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2014 Jun; 2(6):500-12. PMID: 24880565.
      Citations: 26     Fields:    Translation:Humans
    285. Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW, Coleman RE, Seckl MJ. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. J Reprod Med. 2014 Jan-Feb; 59(1-2):7-12. PMID: 24597279.
      Citations: 4     Fields:    Translation:Humans
    286. Pandey SK, Kaur J, Easwaramoorthy B, Shah A, Coleman R, Mukherjee J. Multimodality imaging probe for positron emission tomography and fluorescence imaging studies. Mol Imaging. 2014; 13:1-7. PMID: 24824856.
      Citations: 4     Fields:    Translation:Animals
    287. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014 Jan; 15(1):114-22. PMID: 24332514.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    288. Frumovitz M, Coleman RC, Soliman PT, Ramirez PT, Levenback CF. A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):275-9. PMID: 24291694.
      Citations: 6     Fields:    Translation:Humans
    289. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17. PMID: 24239753.
      Citations: 15     Fields:    Translation:Humans
    290. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75. PMID: 24183729.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    291. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013 Dec 10; 31(35):4400-6. PMID: 24127448.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    292. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43. PMID: 24100628.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    293. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013 Nov; 14(12):1216-25. PMID: 24095299.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    294. Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013 Aug; 87(2):101-11. PMID: 23838481.
      Citations: 16     Fields:    Translation:HumansAnimals
    295. Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets. 2013 Jul; 13(6):698-707. PMID: 23675882.
      Citations: 9     Fields:    Translation:HumansCells
    296. Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 2013 Jul 20; 31(21):2685-91. PMID: 23796998.
      Citations: 16     Fields:    Translation:Humans
    297. Craig CD, Iglesias DA, Watkins J, Coleman RL, Kilgore L, Ramirez PT. Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecol Oncol Case Rep. 2013; 5:64-6. PMID: 24371701.
      Citations: 1     
    298. Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-?B ligand inhibitors in patients with advanced prostate cancer. Eur Urol. 2014 Feb; 65(2):278-86. PMID: 23706567.
      Citations: 13     Fields:    Translation:HumansCells
    299. Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013 May; 9(5):633-43. PMID: 23647292.
      Citations: 11     Fields:    Translation:Humans
    300. Saigal N, Bajwa AK, Faheem SS, Coleman RA, Pandey SK, Constantinescu CC, Fong V, Mukherjee J. Evaluation of serotonin 5-HT(1A) receptors in rodent models using [¹8F]mefway PET. Synapse. 2013 Sep; 67(9):596-608. PMID: 23504990.
      Citations: 12     Fields:    Translation:Animals
    301. Pithia N, Gulati N, Pandey S, Coleman R, Kant R, Mukherjee J. Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging. Nucl Med Biol. 2013 Jul; 40(5):697-704. PMID: 23562464.
      Citations:    Fields:    Translation:Animals
    302. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S, Holen I, Coleman RE. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Clin Cancer Res. 2013 May 15; 19(10):2755-65. PMID: 23515409.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    303. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol. 2013 Jun; 9(6):365-74. PMID: 23507900.
      Citations: 16     Fields:    Translation:Humans
    304. Coleman R, Hadji P. JBO-Launched and flying ahead. J Bone Oncol. 2013 Feb; 2(1):1. PMID: 26909266.
      Citations:    
    305. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013 Jun; 129(3):452-8. PMID: 23474348.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    306. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013; 18(4):353-61. PMID: 23404816.
      Citations: 26     Fields:    Translation:Humans
    307. Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol. 2013 Jun; 2(2):70-6. PMID: 26909273.
      Citations: 11     
    308. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24. PMID: 23381004.
      Citations: 178     Fields:    Translation:Humans
    309. Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA. Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer. 2013 Feb; 23(2):348-54. PMID: 23295941.
      Citations: 3     Fields:    Translation:Humans
    310. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. PMID: 23261356.
      Citations: 111     Fields:    Translation:HumansCellsCTClinical Trials
    311. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. PMID: 23246022.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    312. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012 Dec 12; 12:CD008891. PMID: 23235667.
      Citations: 10     Fields:    Translation:Humans
    313. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94. PMID: 23190436.
      Citations: 8     Fields:    Translation:Humans
    314. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013 Feb; 128(2):155-9. PMID: 23201592.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    315. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11. PMID: 23200915.
      Citations: 12     Fields:    Translation:HumansCells
    316. Schmeler KM, Wilson GL, Cain K, Munsell MF, Ramirez PT, Soliman PT, Nick AM, Frumovitz M, Coleman RL, Kroll MH, Levenback CF. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol. 2013 Feb; 128(2):204-8. PMID: 23200912.
      Citations: 13     Fields:    Translation:Humans
    317. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012 Nov 01; 18(21):5856-64. PMID: 23082003.
      Citations: 120     Fields:    Translation:HumansCells
    318. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34. PMID: 23008289.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    319. Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012 Nov 15; 18(22):6348-55. PMID: 22952345.
      Citations: 23     Fields:    Translation:Humans
    320. Coleman RE. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Curr Opin Support Palliat Care. 2012 Sep; 6(3):322-9. PMID: 22801464.
      Citations: 10     Fields:    Translation:Humans
    321. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43. PMID: 22922531.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    322. Revyakin A, Zhang Z, Coleman RA, Li Y, Inouye C, Lucas JK, Park SR, Chu S, Tjian R. Transcription initiation by human RNA polymerase II visualized at single-molecule resolution. Genes Dev. 2012 Aug 01; 26(15):1691-702. PMID: 22810624.
      Citations: 33     Fields:    Translation:HumansCells
    323. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012 Jul 18; 104(14):1059-67. PMID: 22752060.
      Citations: 80     Fields:    Translation:Humans
    324. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov 01; 30(31):3786-91. PMID: 22753905.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    325. Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med. 2012 Jul-Aug; 57(7-8):293-6. PMID: 22838243.
      Citations: 1     Fields:    Translation:Humans
    326. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013 Feb; 31(1):213-29. PMID: 22661305.
      Citations: 12     Fields:    Translation:HumansCells
    327. Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii. PMID: 22520979.
      Citations: 2     Fields:    Translation:Humans
    328. Coleman R, Hadji P. Bone Oncology-An emerging multi-disciplinary specialty. J Bone Oncol. 2012 Jun; 1(1):1. PMID: 26909247.
      Citations:    
    329. Jassam N, Gopaul S, McShane P, McHugh A, Coleman R, Thompson D, Barth JH. Calcium adjustment equations in neonates and children. Ann Clin Biochem. 2012 Jul; 49(Pt 4):352-8. PMID: 22535865.
      Citations:    Fields:    Translation:Humans
    330. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52. PMID: 22523198.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    331. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    332. Nihira MA, Drake NL, Corton MM, Wai CY, Coleman RL, Quiroz LH. Reported cystoscopic experience correlates poorly with objective assessment of cystoscopic skills. Female Pelvic Med Reconstr Surg. 2012 Mar-Apr; 18(2):97-102. PMID: 22453320.
      Citations:    Fields:    Translation:Humans
    333. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013 Feb; 31(1):77-84. PMID: 22370972.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    334. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5. PMID: 22387451.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    335. Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92. PMID: 22270280.
      Citations: 26     Fields:    Translation:Humans
    336. Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012 Jan 10; 9(2):110-8. PMID: 22231759.
      Citations: 30     Fields:    Translation:HumansCells
    337. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9. PMID: 22390757.
      Citations: 6     Fields:    Translation:Humans
    338. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7. PMID: 22210309.
      Citations:    Fields:    Translation:Humans
    339. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011 Dec 20; 9(2):76-8. PMID: 22182971.
      Citations: 33     Fields:    Translation:Humans
    340. Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7. PMID: 22184398.
      Citations: 7     Fields:    Translation:HumansAnimals
    341. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012 Oct; 38(6):708-14. PMID: 22178456.
      Citations: 56     Fields:    Translation:Humans
    342. Julius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA. Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. J Antimicrob Chemother. 2012 Feb; 67(2):422-9. PMID: 22129592.
      Citations: 1     Fields:    Translation:HumansCells
    343. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46. PMID: 22093187.
      Citations: 245     Fields:    Translation:HumansCTClinical Trials
    344. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94. PMID: 22072418.
      Citations: 46     Fields:    Translation:Humans
    345. Coleman R. Early management and long-term outcomes in primary vesico-ureteric reflux. BJU Int. 2011 Nov; 108 Suppl 2:3-8. PMID: 22085118.
      Citations: 5     Fields:    Translation:Humans
    346. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012 Mar 01; 30(7):709-17. PMID: 22042946.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    347. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17. PMID: 21992853.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    348. Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat. 2012 Jun; 133(2):523-36. PMID: 21956211.
      Citations: 8     Fields:    Translation:AnimalsCells
    349. Aapro MS, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. Breast. 2012 Feb; 21(1):8-19. PMID: 21958673.
      Citations: 8     Fields:    Translation:HumansCells
    350. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612. PMID: 21957230.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    351. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13; 365(15):1396-405. PMID: 21995387.
      Citations: 176     Fields:    Translation:HumansCTClinical Trials
    352. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    353. Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer? Gynecol Oncol. 2011 Sep; 122(3):595-9. PMID: 21684585.
      Citations: 4     Fields:    Translation:Humans
    354. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011 Jul 30; 71(11):1397-412. PMID: 21812505.
      Citations: 38     Fields:    Translation:Humans
    355. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9. PMID: 21795478.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    356. Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 2011 Aug 20; 29(24):3247-54. PMID: 21768453.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    357. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85. PMID: 21753153.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    358. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011 Jul; 21(5):831-6. PMID: 21613957.
      Citations: 5     Fields:    Translation:Humans
    359. Archibald K, Coleman R, Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011 Jun 04; 377(9781):1915. PMID: 21641471.
      Citations: 4     Fields:    Translation:HumansAnimals
    360. Coleman R. Prostate cancer: targeted therapy for prostate cancer metastases to bone. Nat Rev Urol. 2011 May 17; 8(6):296-8. PMID: 21587226.
      Citations:    Fields:    Translation:Humans
    361. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5. PMID: 21497382.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    362. Armstrong DK, Coleman RL, Penson RT. Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol. 2011 Apr; 9(4 Suppl 5):1-16. PMID: 21558997.
      Citations:    Fields:    Translation:Humans
    363. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22. PMID: 21436700.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    364. Constantinescu CC, Coleman RA, Pan ML, Mukherjee J. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹8F]fallypride and [¹8F]desmethoxyfallypride. Synapse. 2011 Aug; 65(8):778-87. PMID: 21218455.
      Citations: 16     Fields:    Translation:Animals
    365. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol. 2011 Dec; 80(3):411-32. PMID: 21411334.
      Citations: 25     Fields:    Translation:Humans
    366. Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2011 Mar; 15(3):501-13. PMID: 20015195.
      Citations: 11     Fields:    Translation:HumansCells
    367. Slomovitz BM, Worley MJ, Markman M, Coleman RL. Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs. 2011 Mar; 16(1):71-84. PMID: 21352070.
      Citations:    Fields:    Translation:Humans
    368. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011 Jul; 49(1):71-6. PMID: 21320652.
      Citations: 47     Fields:    Translation:HumansAnimals
    369. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8. PMID: 21329967.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    370. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8. PMID: 21277623.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    371. Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S31-7. PMID: 21353179.
      Citations: 10     Fields:    Translation:Humans
    372. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011 Mar 10; 29(8):957-62. PMID: 21282539.
      Citations: 42     Fields:    Translation:Humans
    373. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011 May 01; 121(2):323-7. PMID: 21277011.
      Citations: 19     Fields:    Translation:Humans
    374. Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2011 Jan; 21(1):66-71. PMID: 21178571.
      Citations: 4     Fields:    Translation:Humans
    375. Lipton A, Costa L, Coleman RE. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis. 2011; 33(2):59-69. PMID: 22142664.
      Citations: 4     Fields:    Translation:Humans
    376. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer. 2011 Jan 01; 117(1):11-23. PMID: 21235033.
      Citations: 16     Fields:    Translation:Humans
    377. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 Jan 01; 3:82-97. PMID: 21196359.
      Citations: 1     Fields:    Translation:Humans
    378. Ito K, Tsubamoto H, Itani Y, Kuroboshi H, Fujita H, Nobunaga T, Coleman RL. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol. 2011 Feb; 120(2):193-7. PMID: 21075434.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    379. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67. PMID: 21160526.
      Citations: 237     Fields:    Translation:Humans
    380. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010; 12(6):214. PMID: 21176176.
      Citations: 22     Fields:    Translation:HumansAnimals
    381. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14. PMID: 20948320.
      Citations: 22     Translation:HumansAnimalsCells
    382. Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Zoledronic acid. Expert Opin Drug Saf. 2011 Jan; 10(1):133-45. PMID: 21114419.
      Citations: 7     Fields:    Translation:Humans
    383. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34. PMID: 21509770.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    384. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
      Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
    385. Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin. 2010 Dec; 26 Suppl 3:3-20. PMID: 21050131.
      Citations: 13     Fields:    Translation:Humans
    386. Gehlert S, Coleman R. Using community-based participatory research to ameliorate cancer disparities. Health Soc Work. 2010 Nov; 35(4):302-9. PMID: 21171537.
      Citations: 21     Fields:    Translation:Humans
    387. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9. PMID: 20665499.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    388. Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, Dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol. 2010 Oct; 116(4):956-961. PMID: 20859161.
      Citations: 8     Fields:    Translation:Humans
    389. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8. PMID: 21151709.
      Citations: 4     Fields:    Translation:Humans
    390. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99. PMID: 20889728.
      Citations: 161     Translation:HumansAnimalsCells
    391. Coleman R. The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci. 2011 Feb; 1218:3-14. PMID: 20946581.
      Citations: 16     Fields:    Translation:Humans
    392. Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol. 2011 Aug; 79(2):175-88. PMID: 20846875.
      Citations: 4     Fields:    Translation:Humans
    393. Zand B, Euscher ED, Soliman PT, Schmeler KM, Coleman RL, Frumovitz M, Jhingran A, Ramondetta LM, Ramirez PT. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5. PMID: 20837355.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    394. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC, Kilburn LS. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat. 2010 Nov; 124(1):153-61. PMID: 20730486.
      Citations: 19     Fields:    Translation:Humans
    395. Smith AL, Frumovitz M, Schmeler KM, dos Reis R, Nick AM, Coleman RL, Ramirez PT. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol. 2010 Nov; 119(2):183-6. PMID: 20708227.
      Citations: 4     Fields:    Translation:Humans
    396. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97. PMID: 20708159.
      Citations: 180     Fields:    Translation:AnimalsCells
    397. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010 Oct; 119(1):7-17. PMID: 20692025.
      Citations: 36     Fields:    Translation:HumansPHPublic Health
    398. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88. PMID: 20682653.
      Citations: 18     Translation:HumansAnimalsCells
    399. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9. PMID: 20681032.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    400. Price JM, Hancock BW, Tidy J, Everard J, Coleman RE. Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia. J Reprod Med. 2010 Jul-Aug; 55(7-8):301-4. PMID: 20795342.
      Citations:    Fields:    Translation:Humans
    401. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):767-79. PMID: 20574672.
      Citations: 25     Fields:    Translation:Humans
    402. Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat. 2010 Aug; 122(3):787-94. PMID: 20559708.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    403. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010 Jun; 37 Suppl 1:S53-65. PMID: 20682373.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    404. Betsou F, Rimm DL, Watson PH, Womack C, Hubel A, Coleman RA, Horn L, Terry SF, Zeps N, Clark BJ, Miranda LB, Hewitt RE, Elliott GD. What are the biggest challenges and opportunities for biorepositories in the next three to five years? Biopreserv Biobank. 2010 Jun; 8(2):81-8. PMID: 24845936.
      Citations: 7     Fields:    
    405. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20. PMID: 20478658.
      Citations: 55     Fields:    Translation:HumansAnimalsPHPublic Health
    406. Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ, Holen I. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res. 2010; 47(6):481-93. PMID: 20431297.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    407. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010 Apr 15; 116(8):1918-25. PMID: 20166213.
      Citations: 52     Fields:    Translation:HumansCells
    408. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70. PMID: 20388851.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    409. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr; 9(4):985-95. PMID: 20371710.
      Citations: 20     Translation:HumansAnimalsCells
    410. Bhattacharya A, Watts NB, Davis K, Kotowski S, Shukla R, Dwivedi AK, Coleman R. Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosis. J Clin Densitom. 2010 Apr-Jun; 13(2):228-36. PMID: 20347363.
      Citations: 5     Fields:    Translation:Humans
    411. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    412. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM, DeRogatis LR, Ross RJ. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study. Cancer. 2010 Mar 15; 116(6):1592-601. PMID: 20186765.
      Citations: 19     Fields:    Translation:Humans
    413. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol. 2010 Jul; 203(1):68.e1-6. PMID: 20227055.
      Citations: 17     Fields:    Translation:Humans
    414. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May; 11(5):465-75. PMID: 20226736.
      Citations: 27     Fields:    Translation:Humans
    415. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010 Mar; 10(3):431-7. PMID: 20092424.
      Citations: 28     Fields:    Translation:Humans
    416. Brown JE, Coleman RE. Biomarkers of bone turnover in oncology: applications in diagnosis and treatment. Expert Opin Med Diagn. 2010 Mar; 4(2):125-38. PMID: 23484446.
      Citations: 1     Fields:    
    417. Din OS, Dodwell D, Wakefield RJ, Coleman RE. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010 Apr; 120(3):525-38. PMID: 20157776.
      Citations: 16     Fields:    Translation:HumansAnimals
    418. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82. PMID: 20009575.
      Citations: 29     Translation:HumansAnimalsCells
    419. Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol. 2010 Feb; 116(2):155-6. PMID: 20109724.
      Citations: 1     Fields:    Translation:Humans
    420. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010 Jan 15; 126(2):522-32. PMID: 19621384.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    421. Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des. 2010; 16(11):1262-71. PMID: 20166976.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    422. Coleman RE, Walsh JS. Bone: causes of low bone mass in breast cancer-time for action? Nat Rev Endocrinol. 2010 Jan; 6(1):10-2. PMID: 20010963.
      Citations:    Fields:    Translation:Humans
    423. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72. PMID: 19829059.
      Citations: 9     Translation:AnimalsCells
    424. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S63-7. PMID: 19955917.
      Citations: 23     Fields:    Translation:Humans
    425. Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP, Coleman RE. The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. Bone. 2010 Mar; 46(3):801-5. PMID: 19931437.
      Citations: 1     Fields:    Translation:Humans
    426. Coleman RL. Emergence of truly "individualized" therapy: the poly (adenosine diphosphate-ribose) polymerase inhibitors. Curr Oncol Rep. 2009 Nov; 11(6):414-6. PMID: 19840517.
      Citations:    Fields:    
    427. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol. 2009 Nov; 21(6):499-506. PMID: 19730102.
      Citations: 10     Fields:    Translation:Humans
    428. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther. 2009 Oct; 8(10):2821-32. PMID: 19789217.
      Citations: 24     Translation:HumansAnimalsCells
    429. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009 Oct 17; 374(9698):1371-82. PMID: 19793610.
      Citations: 221     Fields:    Translation:HumansPHPublic Health
    430. Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care. 2009 Sep; 3(3):213-8. PMID: 19561507.
      Citations: 3     Fields:    Translation:HumansCells
    431. Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy? Breast Care (Basel). 2009; 4(4):268-271. PMID: 20877666.
      Citations:    
    432. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603. PMID: 19738426.
      Citations: 21     Translation:HumansAnimalsCells
    433. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009 Aug 06; 9:272. PMID: 19660124.
      Citations: 18     Fields:    Translation:Humans
    434. Dodwell D, Thorpe H, Coleman R. Refining systemic therapy for early breast cancer: difficulties with subtraction. Lancet Oncol. 2009 Aug; 10(8):738-9. PMID: 19647192.
      Citations: 1     Fields:    Translation:Humans
    435. Levenback CF, van der Zee AG, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol. 2009 Aug; 114(2):151-6. PMID: 19457548.
      Citations: 10     Fields:    Translation:Humans
    436. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205. PMID: 19641174.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    437. Liu WL, Coleman RA, Ma E, Grob P, Yang JL, Zhang Y, Dailey G, Nogales E, Tjian R. Structures of three distinct activator-TFIID complexes. Genes Dev. 2009 Jul 01; 23(13):1510-21. PMID: 19571180.
      Citations: 40     Fields:    Translation:HumansCells
    438. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34. PMID: 19395869.
      Citations: 30     Translation:HumansAnimals
    439. Aboumarzouk OM, Coleman R, Goepel JR, Shorthouse AJ. PNET/Ewing's sarcoma of the rectum: a case report and review of the literature. BMJ Case Rep. 2009; 2009. PMID: 21691396.
      Citations: 1     Fields:    
    440. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92. PMID: 19396818.
      Citations: 33     Fields:    Translation:Humans
    441. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep; 114(3):431-6. PMID: 19524286.
      Citations: 13     Fields:    Translation:Humans
    442. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat. 2010 Feb; 119(3):717-24. PMID: 19495958.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    443. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600. PMID: 19519199.
      Citations: 11     Fields:    Translation:Humans
    444. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80. PMID: 19470734.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    445. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16; 373(9676):1681-92. PMID: 19447249.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    446. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52. PMID: 19361839.
      Citations: 61     Fields:    Translation:Humans
    447. Santoso JT, Azadi A, Wan J, Handorf C, Coleman RL, Tillmanns TD. Lymph node counts in uterine cancer: a randomized double blind trial. Gynecol Oncol. 2009 May; 113(2):159-62. PMID: 19268343.
      Citations: 2     Fields:    Translation:Humans
    448. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009 Mar-Apr; 15(2):176-81. PMID: 19292804.
      Citations: 2     Fields:    Translation:Humans
    449. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53. PMID: 19058181.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    450. Kamat AA, Coleman RL. Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox. Cancer Biol Ther. 2009 Jan; 8(1):18-20. PMID: 19127119.
      Citations:    Translation:Humans
    451. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50. PMID: 19092150.
      Citations: 322     Fields:    Translation:HumansCells
    452. Coleman RE. Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer. Nat Clin Pract Endocrinol Metab. 2009 Feb; 5(2):72-3. PMID: 19065127.
      Citations: 1     Fields:    
    453. Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT. Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol. 2008 Nov-Dec; 15(6):723-8. PMID: 18971136.
      Citations:    Fields:    Translation:Humans
    454. Coleman RL. Lymphatic mapping for vulvar cancer: ready for "prime-time?". Curr Oncol Rep. 2008 Nov; 10(6):493-6. PMID: 18928663.
      Citations:    Fields:    
    455. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008 Oct 15; 14(20):6690-6. PMID: 18927312.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    456. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95. PMID: 18927277.
      Citations: 21     Fields:    Translation:Humans
    457. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6336-42. PMID: 18829518.
      Citations: 54     Fields:    Translation:Humans
    458. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73. PMID: 18834619.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    459. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46. PMID: 18765535.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    460. Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do we have one? Cancer. 2008 Aug 15; 113(4):665-7. PMID: 18623195.
      Citations: 1     Fields:    Translation:Humans
    461. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20; 100(16):1167-78. PMID: 18695136.
      Citations: 70     Fields:    Translation:HumansAnimals
    462. Coleman RL, Levine DA. 44th Annual Meeting of the American Society of Clinical Oncology. Gynecol Oncol. 2008 Aug; 110(2):123-4. PMID: 18649408.
      Citations:    Fields:    Translation:Humans
    463. Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod. 2008 Nov; 23(11):2506-12. PMID: 18664468.
      Citations: 11     Fields:    Translation:Humans
    464. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008 Jul 15; 14(14):4658-66. PMID: 18628481.
      Citations: 29     Fields:    Translation:HumansAnimals
    465. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58. PMID: 18632639.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    466. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008 Jul 01; 113(1):193-201. PMID: 18459173.
      Citations: 62     Fields:    Translation:Humans
    467. Coleman RL. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S77-80. PMID: 18584855.
      Citations: 2     Fields:    Translation:Humans
    468. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39. PMID: 18579314.
      Citations: 31     Fields:    Translation:Humans
    469. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008; 34 Suppl 1:S3-18. PMID: 18515009.
      Citations: 67     Fields:    Translation:Humans
    470. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev. 2008; 34 Suppl 1:S31-42. PMID: 18486346.
      Citations: 13     Fields:    Translation:Humans
    471. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008 Jul; 110(1):56-9. PMID: 18457865.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    472. Fallowfield L, Jenkins V, Coleman R. Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. Breast. 2008 Oct; 17(5):459-63. PMID: 18455921.
      Citations: 1     Fields:    Translation:Humans
    473. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008 May; 13(5):503-14. PMID: 18515735.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    474. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PMID: 18395047.
      Citations: 21     Fields:    Translation:AnimalsCells
    475. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008 Mar 01; 112(5):1001-10. PMID: 18205185.
      Citations: 61     Fields:    Translation:Humans
    476. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 Mar 01; 26(7):1051-7. PMID: 18309940.
      Citations: 106     Fields:    Translation:Humans
    477. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36. PMID: 18317064.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    478. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr; 5(4):194-204. PMID: 18268546.
      Citations: 49     Fields:    Translation:Humans
    479. Liu WL, Coleman RA, Grob P, King DS, Florens L, Washburn MP, Geles KG, Yang JL, Ramey V, Nogales E, Tjian R. Structural changes in TAF4b-TFIID correlate with promoter selectivity. Mol Cell. 2008 Jan 18; 29(1):81-91. PMID: 18206971.
      Citations: 38     Fields:    Translation:HumansCells
    480. Frumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008 Mar; 108(3):478-81. PMID: 18190952.
      Citations: 4     Fields:    Translation:Humans
    481. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ. 2008; 23(4):235-7. PMID: 19058072.
      Citations: 15     Fields:    Translation:Humans
    482. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4. PMID: 18155273.
      Citations: 59     Fields:    Translation:Humans
    483. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95. PMID: 18094433.
      Citations: 58     Fields:    Translation:HumansAnimals
    484. Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S11-6. PMID: 18068485.
      Citations: 4     Fields:    Translation:HumansAnimals
    485. Coleman RE. Preserving skeletal wellness throughout the continuum of care in patients with cancer. Introduction. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S1-3. PMID: 18068484.
      Citations:    Fields:    Translation:Humans
    486. Isonishi S, Coleman RL, Hirama M, Iida Y, Kitai S, Nagase M, Ochiai K. Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization. Am J Obstet Gynecol. 2008 Mar; 198(3):270.e1-6. PMID: 17997392.
      Citations: 5     Fields:    Translation:Humans
    487. Coleman RL. Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep. 2007 Nov; 9(6):469-71. PMID: 17991354.
      Citations:    Fields:    
    488. Coleman RE. The benefits and costs of bisphosphonates. J Support Oncol. 2007 Nov-Dec; 5(10):483-4. PMID: 18240670.
      Citations: 1     Fields:    Translation:Humans
    489. Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr; 17(2):180-5. PMID: 17976988.
      Citations: 10     Fields:    Translation:Humans